Loading...
•
Dec 31, 2023
Prothena Q4 2023 Earnings Report
Prothena reported a net loss for Q4 2023, driven by increased R&D and G&A expenses, despite revenue from BMS collaboration.
Key Takeaways
Prothena reported a net loss of $67.5 million in Q4 2023, compared to a net income of $6.3 million in Q4 2022. The loss was primarily due to increased research and development and general and administrative expenses. Total revenue was $0.3 million, including BMS collaboration revenue.
Net loss was $67.5 million, compared to a net income of $6.3 million in the same period last year.
Total revenue was $0.3 million, including BMS collaboration revenue.
Net cash used in operating and investing activities was $52.6 million.
Cash and restricted cash position at quarter-end was $621.0 million.
Prothena
Prothena
Prothena Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The company expects full year 2024 net cash used in operating and investing activities to be $208 to $225 million and expects to end the year with approximately $405 million in cash, cash equivalents and restricted cash (midpoint).